Avalon GloboCare (ALBT) Competitors

Avalon GloboCare (NASDAQ:ALBT) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings.

Do insiders and institutionals hold more shares of ALBT or PASG?

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 37.3% of Avalon GloboCare shares are owned by insiders. Comparatively, 5.0% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the media refer more to ALBT or PASG?

In the previous week, Avalon GloboCare had 1 more articles in the media than Passage Bio. MarketBeat recorded 2 mentions for Avalon GloboCare and 1 mentions for Passage Bio. Passage Bio's average media sentiment score of 1.87 beat Avalon GloboCare's score of 1.43 indicating that Passage Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalon GloboCare	Positive
Passage Bio	Very Positive

Which has more risk and volatility, ALBT or PASG?

Avalon GloboCare has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Do analysts prefer ALBT or PASG?

Passage Bio has a consensus target price of $7.50, indicating a potential upside of 1,637.32%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts plainly believe Passage Bio is more favorable than Avalon GloboCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Passage Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is ALBT or PASG more profitable?

Passage Bio has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,125.59%. Avalon GloboCare's return on equity of 0.00% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	-1,125.59%	N/A	-73.69%
Passage Bio	N/A	-72.53%	-52.10%

Which has higher valuation & earnings, ALBT or PASG?

Avalon GloboCare has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.37M	4.18	-$16.71M	-$19.96	-0.15
Passage Bio	N/A	N/A	-$102.06M	-$1.02	-0.42

Does the MarketBeat Community prefer ALBT or PASG?

Passage Bio received 53 more outperform votes than Avalon GloboCare when rated by MarketBeat users.

Company	Underperform	Outperform
Avalon GloboCare	N/A	N/A
Passage Bio	Outperform Votes 53 68.83%	Underperform Votes 24 31.17%

Summary

Passage Bio beats Avalon GloboCare on 10 of the 16 factors compared between the two stocks.